PharmacoEconomics

Recent National and Regional Drug Reforms in Sweden: Implications for Pharmaceutical Companies in Europe
pp. 537-550(14)
Authors: Wettermark, Björn; Godman, Brian; Andersson, Karolina; Gustafsson, Lars L.; Haycox, Alan; Bertele′, Vittorio

Pharmaceutical Risk-Sharing Agreements
pp. 551-556(6)
Authors: Cook, Joseph P.; Vernon, John A.; Manning, Richard

Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?
pp. 557-566(10)
Authors: Jureidini, Jon; Mintzes, Barbara; Raven, Melissa

The Author's Reply
pp. 567-568(2)
Author: Block, Adam E.

Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes: A Systematic Review on Content and Adherence to Guidelines
pp. 569-587(19)
Authors: Vegter, Stefan; Boersma, Cornelis; Rozenbaum, Mark; Wilffert, Bob; Navis, GerJan; Postma, Maarten J.

Future Drug Prices and Cost-Effectiveness Analyses
pp. 589-602(14)
Author: Hoyle, Martin

Generic Entry, Reformulations and Promotion of SSRIs in the US
pp. 603-616(14)
Authors: Huskamp, Haiden A.; Donohue, Julie M.; Koss, Catherine; Berndt, Ernst R.; Frank, Richard G.

Cost-Effectiveness Analyses of Natalizumab (Tysabri^®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
pp. 617-627(11)
Authors: Gani, Ray; Giovannoni, Gavin; Bates, David; Kemball, Belinda; Hughes, Steve; Kerrigan, John